Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 11, Pages 2603
Publisher
MDPI AG
Online
2021-05-26
DOI
10.3390/cancers13112603
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress
- (2021) Shun Lu et al. Clinical Lung Cancer
- Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
- (2021) Li Sun et al. Frontiers in Oncology
- Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
- (2021) Caroline Huynh et al. Translational Lung Cancer Research
- The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
- (2021) Long Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response
- (2021) Philipp Zens et al. MODERN PATHOLOGY
- P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
- (2021) M. Tsuboi et al. Journal of Thoracic Oncology
- Colorectal cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series
- (2020) Weian Song et al. Thoracic Cancer
- Role of MPR as an early signal for efficacy in neoadjuvant studies
- (2020) Collin M. Blakely et al. CLINICAL CANCER RESEARCH
- Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
- (2020) Catherine A Shu et al. LANCET ONCOLOGY
- Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
- (2020) Jordi Remon et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
- (2020) Mariano Provencio et al. LANCET ONCOLOGY
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
- (2020) Joshua E Reuss et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
- (2020) Rilan Bai et al. Frontiers in Oncology
- Radical surgical resection after neoadjuvant targeted therapy in non-small cell lung cancer: a single-center retrospective study of 6 cases
- (2019) Zhenyang Zhang et al. Journal of Thoracic Disease
- Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
- (2019) Florian Eichhorn et al. BMC CANCER
- Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
- (2019) Wen-Zhao Zhong et al. JOURNAL OF CLINICAL ONCOLOGY
- Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
- (2019) Chengxiang Yi et al. OncoTargets and Therapy
- P2.04-28 NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I–IIIA) Non-Small Cell Lung Cancer
- (2019) R. Garcia Campelo et al. Journal of Thoracic Oncology
- P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
- (2019) J. Heymach et al. Journal of Thoracic Oncology
- P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)
- (2019) N. Altorki et al. Journal of Thoracic Oncology
- Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors
- (2018) Matthew J. Bott et al. ANNALS OF THORACIC SURGERY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
- (2018) Justin Yeh et al. Journal of Thoracic Disease
- Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
- (2018) Hiran C. Fernando et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)EGFRMutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
- (2018) Liwen Xiong et al. ONCOLOGIST
- Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer
- (2018) Matthew J. Bott et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
- (2017) Heather Wakelee et al. Journal of Thoracic Oncology
- Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer
- (2017) Sarah J. Gao et al. Journal of Thoracic Oncology
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
- (2015) W. E. E. Eberhardt et al. ANNALS OF ONCOLOGY
- Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
- (2015) Wilfried Ernst Erich Eberhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status
- (2015) Wenzhao Zhong et al. Journal of Hematology & Oncology
- Surgical Resection of Locally Advanced Pulmonary Adenocarcinoma After Gefitinib Therapy
- (2011) Ming Liu et al. ANNALS OF THORACIC SURGERY
- Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer
- (2010) Paul De Leyn et al. Journal of Thoracic Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started